COGNITION THERAPEUTICS INC Financials
This page shows COGNITION THERAPEUTICS INC (CGTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is sustaining a persistent operating cash consumer as research spending remains the dominant business investment.
In FY2025, operating cash flow of-$24.6M nearly matched the net loss of-$23.5M , indicating that accounting losses are translating into cash needs rather than being mainly non-cash charges. That relationship also held in FY2024, so the earnings profile is defined by cash consumption, not a temporary working-capital distortion.
Cash rose from
Financing inflows coincided with shares outstanding rising from 59.9M to 88.9M, pointing to equity-linked funding rather than self-financing operations. The reported current ratio of 3.4x and debt-to-equity ratio of 0.4x indicate near-term liquidity is stronger than the recurring loss profile, but maintaining that position depends on continued access to capital.
Financial Health Signals
COGNITION THERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
COGNITION THERAPEUTICS INC passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
COGNITION THERAPEUTICS INC reported a net loss of $23.5M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
COGNITION THERAPEUTICS INC's EBITDA was -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.3% from the prior year.
COGNITION THERAPEUTICS INC reported -$23.5M in net income in fiscal year 2025. This represents an increase of 30.9% from the prior year.
COGNITION THERAPEUTICS INC earned -$0.32 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
COGNITION THERAPEUTICS INC held $36.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
COGNITION THERAPEUTICS INC's ROE was -68.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 112.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
COGNITION THERAPEUTICS INC invested $37.2M in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CGTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $37.2M-10.8% | $41.7M+12.0% | $37.2M+22.7% | $30.3M+63.3% | $18.6M+44.1% | $12.9M |
| SG&A Expenses | N/A | $10.6M-13.7% | $12.3M-9.2% | $13.5M+2.3% | $13.2M+31.9% | $10.0M+121.8% | $4.5M |
| Operating Income | N/A | -$47.8M+11.4% | -$54.0M-6.4% | -$50.7M-16.5% | -$43.6M-52.3% | -$28.6M-64.3% | -$17.4M |
| Interest Expense | N/A | N/A | N/A | -$27K+3.6% | -$28K-103.1% | $895K-49.1% | $1.8M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$23.5M+30.9% | -$34.0M-31.7% | -$25.8M-20.5% | -$21.4M-82.6% | -$11.7M-49.5% | -$7.8M |
| EPS (Diluted) | — | -$0.32 | -$0.86 | -$0.86+5.5% | -$0.91 | -$3.13 | -$23.76 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CGTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $48.4M+60.1% | $30.2M-14.0% | $35.2M-30.3% | $50.4M-14.7% | $59.1M+730.7% | $7.1M |
| Current Assets | $48.0M+62.4% | $29.6M-13.6% | $34.2M-28.2% | $47.6M-19.2% | $59.0M+754.0% | $6.9M |
| Cash & Equivalents | $36.8M+47.2% | $25.0M-16.4% | $29.9M-28.0% | $41.6M-24.0% | $54.7M+954.6% | $5.2M |
| Total Liabilities | $14.1M+22.9% | $11.5M+7.4% | $10.7M+5.0% | $10.2M+29.4% | $7.9M-89.6% | $75.3M |
| Current Liabilities | $13.9M+25.0% | $11.1M+9.6% | $10.2M+30.5% | $7.8M-0.9% | $7.9M+142.0% | $3.3M |
| Total Equity | $34.3M+82.8% | $18.8M-23.4% | $24.5M-39.2% | $40.2M-21.5% | $51.3M+175.2% | -$68.2M |
| Retained Earnings | -$198.6M-13.4% | -$175.2M-24.1% | -$141.2M-22.3% | -$115.4M-22.8% | -$94.0M-37.8% | -$68.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CGTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.7M | -$24.6M+13.6% | -$28.5M-77.8% | -$16.0M+13.6% | -$18.5M-410.4% | -$3.6M-5.8% | -$3.4M |
| Capital Expenditures | N/A | N/A | $4K-97.3% | $147K-14.0% | $171K+533.3% | $27K+170.0% | $10K |
| Free Cash Flow | N/A | N/A | -$28.5M-76.2% | -$16.2M+13.6% | -$18.7M-411.3% | -$3.7M-6.2% | -$3.4M |
| Investing Cash Flow | N/A | $9K+325.0% | -$4K+97.3% | -$147K+14.0% | -$171K-533.3% | -$27K-170.0% | -$10K |
| Financing Cash Flow | $40.9M | $36.6M+55.2% | $23.6M+421.2% | $4.5M-18.5% | $5.5M-89.6% | $53.2M+822.8% | $5.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CGTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -68.5%+112.7pp | -181.2%-75.8pp | -105.4%-52.2pp | -53.2%-30.3pp | -22.9% | N/A |
| Return on Assets | -48.5%+63.8pp | -112.4%-39.0pp | -73.3%-30.9pp | -42.4%-22.6pp | -19.8%+90.3pp | -110.1% |
| Current Ratio | 3.45+0.8x | 2.65-0.7x | 3.37-2.7x | 6.11-1.4x | 7.50+5.4x | 2.13 |
| Debt-to-Equity | 0.41-0.2x | 0.61+0.2x | 0.44+0.2x | 0.25+0.1x | 0.15 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where COGNITION THERAPEUTICS INC Ranks
Frequently Asked Questions
Is COGNITION THERAPEUTICS INC profitable?
No, COGNITION THERAPEUTICS INC (CGTX) reported a net income of -$23.5M in fiscal year 2025.
What is COGNITION THERAPEUTICS INC's EBITDA?
COGNITION THERAPEUTICS INC (CGTX) had EBITDA of -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is COGNITION THERAPEUTICS INC's return on equity (ROE)?
COGNITION THERAPEUTICS INC (CGTX) has a return on equity of -68.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is COGNITION THERAPEUTICS INC's operating cash flow?
COGNITION THERAPEUTICS INC (CGTX) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are COGNITION THERAPEUTICS INC's total assets?
COGNITION THERAPEUTICS INC (CGTX) had $48.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does COGNITION THERAPEUTICS INC spend on research and development?
COGNITION THERAPEUTICS INC (CGTX) invested $37.2M in research and development during fiscal year 2025.
What is COGNITION THERAPEUTICS INC's current ratio?
COGNITION THERAPEUTICS INC (CGTX) had a current ratio of 3.45 as of fiscal year 2025, which is generally considered healthy.
What is COGNITION THERAPEUTICS INC's debt-to-equity ratio?
COGNITION THERAPEUTICS INC (CGTX) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is COGNITION THERAPEUTICS INC's return on assets (ROA)?
COGNITION THERAPEUTICS INC (CGTX) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is COGNITION THERAPEUTICS INC's cash runway?
Based on fiscal year 2025 data, COGNITION THERAPEUTICS INC (CGTX) had $36.8M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is COGNITION THERAPEUTICS INC's Piotroski F-Score?
COGNITION THERAPEUTICS INC (CGTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are COGNITION THERAPEUTICS INC's earnings high quality?
COGNITION THERAPEUTICS INC (CGTX) reported a net loss of $23.5M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.